Special Issue "Nanotechnology and Cancer Therapeutics"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2010)
Prof. Dr. Shaker A. Mousa
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, NY 12144, USA
Fax: +1 518-694 7567
Interests: pharmaceuticals, biopharmaceuticals, and diagnostics; nanomedicine; cardiovascular diseases; neurological disorders; hematology and oncology; biosimilar and nanosimilar; angiogenesis, inflammation, thrombosis, integrin and cell adhesion molecules; target identification, molecular mechanisms and signaling pathways; preclinical, clinical, marketing and post marketing studies; regulatory and ethical issues
I would like to take this opportunity in inviting review articles having key innovations that would help accelerate progress in the field of Nanotechnology in early cancer detection and treatment. It is becoming clear to all of us that the application of nanotechnology and biotechnology utilizing nanoparticles for combined targeting and delivery of diagnostic and therapeutic agents has tremendous potential for early detection and treatment of various disorders. Nanoparticles may be constructed from a wide range of organic and inorganic materials such as emulsions, micelles, liposomes, dendrimers, quantum dots, and other polymeric materials. These materials are being used to encapsulate or covalently bind to the surface of the nanoparticles site directed moiety (s). Several multifunctional nanoparticles are being evaluated in early detection and therapeutics.
The next generation of nanoparticles-based research is directed at the consolidation of functions into strategically engineered multifunctional devices, which may ultimately facilitate the realization of individual therapy. These nanoparticles may be capable of (a) improving delivery of hydrophobic compounds (water insoluble); (b) improving stability of unstable peptides or easily inactivated compounds such as polyphenols and others; (c) identifying malignant cells via molecular detection; (c) visualizing their location in the body by providing enhanced contrast in medical imaging techniques; (d) targeting and killing diseased cells with minimal side effects through selective cell or tissue targeting; (e) polyvalent antidote for reversal of intoxication or toxins; and (f) delivering multiple drug targets for combination therapy.
One of the best known examples for reformulated, nanoparticles-based drug delivery is Doxil. Doxil, approved in the U.S. in 1995, is the poly (ethylene glycol)-coated, liposome-encapsulated form of doxorubicin in cancer chemotherapy. A more recent commercial product Abraxane, consists of an albumin-based reformulation of paclitaxel, which was approved in the U.S. in 2005. Other examples are in preclinical and early clinical investigations.
Dr. Shaker A. Mousa
- early detection using in vivo imaging modalities
- site directed delivery of chemotherapy into different tumor types using specific directed targets metal nanoparticles such as gold nanoparticles in the detection and treatment of breast cancer, and other types of cancer
- use of nanotechnology with nutraceuticals for chemoprevention